These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34380864)

  • 1. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.
    Ni YC; Zhao JG; Zhang MN; Zhang YJ; Yang ZY; Chen N; Chen JR; Shen PF; Sun GX; Zhang XM; Li YH; Zeng H
    Asian J Androl; 2022; 24(2):154-160. PubMed ID: 34380864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
    Yang Z; Ni Y; Zhao D; Zhang Y; Wang J; Jiang L; Chen D; Wu Z; Wang Y; He L; Shi Y; Zhou F; Zeng H; Li Y
    BMC Cancer; 2021 Aug; 21(1):919. PubMed ID: 34388965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
    Romero-Laorden N; Lozano R; Jayaram A; López-Campos F; Saez MI; Montesa A; Gutierrez-Pecharoman A; Villatoro R; Herrera B; Correa R; Rosero A; Pacheco MI; Garcés T; Cendón Y; Nombela MP; Van de Poll F; Grau G; Rivera L; López PP; Cruz JJ; Lorente D; Attard G; Castro E; Olmos D
    Br J Cancer; 2018 Oct; 119(9):1052-1059. PubMed ID: 30131546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
    BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
    Fizazi K; Flaig TW; Stöckle M; Scher HI; de Bono JS; Rathkopf DE; Ryan CJ; Kheoh T; Li J; Todd MB; Griffin TW; Molina A; Ohlmann CH
    Ann Oncol; 2016 Apr; 27(4):699-705. PubMed ID: 26609008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Fang WY; Wang PF; Fan YC; Shih HJ
    Urol Int; 2021; 105(5-6):380-385. PubMed ID: 32791510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
    Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
    Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone.
    Sheng IY; Fallah J; Gupta R; Li H; Allman K; Martin A; Barata P; Ornstein MC; Gilligan TD; Rini BI; Garcia JA
    Target Oncol; 2020 Aug; 15(4):477-483. PubMed ID: 32661959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
    Xiong X; Qiu S; Yi X; Xu H; Liao D; Lei H; Bai S; Peng G; Ai J; Yang L
    Urol Oncol; 2021 Nov; 39(11):754-763. PubMed ID: 34330654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort.
    Lim J; Amantakul A; Shariff N; Lojanapiwat B; Alip A; Ong TA; Thevarajah S; Ahmayuddin F; Mathew A; Sriplakich S; Vuthiwong J; Chong FLT; Saad M
    Cancer Med; 2020 Jul; 9(13):4613-4621. PubMed ID: 32374087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.